AVEO
Income statement / Annual
Last year (2021), AVEO Pharmaceuticals, Inc.'s total revenue was $38.87 M,
an increase of 545.85% from the previous year.
In 2021, AVEO Pharmaceuticals, Inc.'s net income was -$61.18 M.
See AVEO Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$38.87 M |
$6.02 M |
$28.80 M |
$5.41 M |
$7.58 M |
$2.52 M |
$19.02 M |
$18.12 M |
$1.29 M |
$19.29 M |
| Cost of Revenue |
$4.74 M
|
$1.25 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$34.14 M
|
$4.77 M
|
$28.80 M
|
$5.41 M
|
$7.58 M
|
$2.52 M
|
$19.02 M
|
$18.12 M
|
$1.29 M
|
$19.29 M
|
| Gross Profit Ratio |
0.88
|
0.79
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$26.30 M
|
$22.68 M
|
$17.96 M
|
$20.65 M
|
$25.18 M
|
$23.70 M
|
$12.88 M
|
$38.25 M
|
$68.47 M
|
$91.36 M
|
| General & Administrative Expenses |
$0.00
|
$22.22 M
|
$11.21 M
|
$10.78 M
|
$9.14 M
|
$8.21 M
|
$14.22 M
|
$18.59 M
|
$28.71 M
|
$36.93 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$60.81 M
|
$22.22 M
|
$11.21 M
|
$10.78 M
|
$9.14 M
|
$8.21 M
|
$14.22 M
|
$18.59 M
|
$28.71 M
|
$36.93 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$4.36 M
|
$11.73 M
|
$8.02 M
|
$2.63 M
|
| Operating Expenses |
$87.11 M
|
$44.90 M
|
$29.17 M
|
$31.43 M
|
$34.32 M
|
$31.91 M
|
$27.09 M
|
$56.84 M
|
$97.18 M
|
$128.29 M
|
| Cost And Expenses |
$91.85 M
|
$44.90 M
|
$29.17 M
|
$31.43 M
|
$34.32 M
|
$31.91 M
|
$27.09 M
|
$56.84 M
|
$97.18 M
|
$128.29 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$21,000.00
|
$32,000.00
|
$125,000.00
|
$497,000.00
|
| Interest Expense |
-$4.05 M
|
$1.61 M
|
$1.82 M
|
$2.19 M
|
$2.37 M
|
$1.95 M
|
$2.31 M
|
$2.39 M
|
$3.13 M
|
$3.50 M
|
| Depreciation & Amortization |
-$7.83 M
|
$21,000.00
|
$11.58 M
|
$22.22 M
|
-$33.74 M
|
$30,000.00
|
$9.57 M
|
$6.22 M
|
$3.78 M
|
$2.51 M
|
| EBITDA |
-$57.39 M |
-$33.96 M |
$11.20 M |
-$3.14 M |
-$62.55 M |
-$24.81 M |
-$3.13 M |
-$44.13 M |
-$100.13 M |
-$108.38 M |
| EBITDA Ratio |
-1.48
|
-5.64
|
0.39
|
-0.58
|
-8.25
|
-9.86
|
-0.16
|
-2.44
|
-77.44
|
-5.62
|
| Operating Income Ratio |
-1.27
|
-6.46
|
-0.01
|
-4.69
|
-3.8
|
-11.69
|
-0.65
|
-2.78
|
-80.36
|
-5.79
|
| Total Other Income/Expenses Net |
-$3.79 M
|
$3.29 M
|
$9.76 M
|
$20.03 M
|
-$36.11 M
|
$2.61 M
|
-$2.58 M
|
-$2.29 M
|
-$3.13 M
|
-$2.76 M
|
| Income Before Tax |
-$53.34 M
|
-$35.58 M
|
$9.39 M
|
-$5.33 M
|
-$64.92 M
|
-$26.79 M
|
-$15.00 M
|
-$52.74 M
|
-$107.03 M
|
-$114.39 M
|
| Income Before Tax Ratio |
-1.37
|
-5.91
|
0.33
|
-0.99
|
-8.57
|
-10.65
|
-0.79
|
-2.91
|
-82.78
|
-5.93
|
| Income Tax Expense |
$7.83 M
|
$4.90 M
|
$0.00
|
$0.00
|
$101,000.00
|
$101,000.00
|
-$268,000.00
|
$98,000.00
|
$2,000.00
|
$744,000.00
|
| Net Income |
-$61.18 M
|
-$35.58 M
|
$9.39 M
|
-$5.33 M
|
-$65.03 M
|
-$26.89 M
|
-$15.00 M
|
-$52.74 M
|
-$107.03 M
|
-$114.39 M
|
| Net Income Ratio |
-1.57
|
-5.91
|
0.33
|
-0.99
|
-8.58
|
-10.69
|
-0.79
|
-2.91
|
-82.78
|
-5.93
|
| EPS |
-2.86 |
-1.66 |
0.61 |
-0.41 |
-6.14 |
-3.88 |
-2.69 |
-10.09 |
-21.02 |
-26.37 |
| EPS Diluted |
-2.86 |
-1.66 |
0.61 |
-0.41 |
-6.14 |
-3.88 |
-2.69 |
-10.09 |
-21.02 |
-26.37 |
| Weighted Average Shares Out |
$21.40 M
|
$21.40 M
|
$15.38 M
|
$13.07 M
|
$10.59 M
|
$6.93 M
|
$5.57 M
|
$5.23 M
|
$5.09 M
|
$4.34 M
|
| Weighted Average Shares Out Diluted |
$21.40 M
|
$21.40 M
|
$15.38 M
|
$13.07 M
|
$10.59 M
|
$6.93 M
|
$5.57 M
|
$5.23 M
|
$5.09 M
|
$4.34 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
